TY - JOUR T1 - Remote monitoring of progression in early Parkinson’s disease: reliability and validity of the Roche PD Mobile Application v2 JF - medRxiv DO - 10.1101/2021.10.07.21264414 SP - 2021.10.07.21264414 AU - Florian Lipsmeier AU - Kirsten I. Taylor AU - Ronald B. Postuma AU - Ekaterina Volkova-Volkmar AU - Timothy Kilchenmann AU - Brit Mollenhauer AU - Atieh Bamdadian AU - Werner L. Popp AU - Wei-Yi Cheng AU - Yan Ping Zhang AU - Detlef Wolf AU - Jens Schjodt-Eriksen AU - Anne Boulay AU - Hanno Svoboda AU - Wagner Zago AU - Gennaro Pagano AU - Michael Lindemann Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/10/2021.10.07.21264414.abstract N2 - Digital health technologies (DHTs) enable remote and therefore frequent measurement of motor signs, potentially providing reliable and valid estimates of motor sign severity and progression in Parkinson’s disease (PD). The Roche PD Mobile Application v1 was revised to v2 to include more measures of bradykinesia, and bradyphrenia and speech tests, to optimize suitability for early-stage PD. It was studied in 316 early-stage PD participants who performed daily active tests at home then carried a smartphone and wore a smartwatch throughout the day for passive monitoring (study NCT03100149). Adherence was excellent (96.29%). All pre-specified sensor features exhibited good-to-excellent test-retest reliability (median intraclass correlation coefficient = 0.9), and correlated with corresponding Movement Disorder Society - Unified Parkinson’s Disease Rating Scale items (rho: 0.12–0.71). These findings demonstrate the preliminary reliability and validity of remote at-home quantification of motor sign severity with the Roche PD Mobile Application v2 in individuals with early PD.Competing Interest StatementFL, KT, EVV, TK, AB, WP, WYC, YPZ, DW, JSE, ABo, HS and GP reports personal fees from F. Hoffmann-La Roche Ltd. BM reports personal fees and other from F. Hoffmann-La Roche Ltd, during the conduct of the study; personal fees from Biogen, personal fees from Servier, non-financial support from Amprion, grants and personal fees from Michael J. Fox Foundation for Parkinson's Research, grants from DFG, grants from EU (Horizon2020), grants from Parkinson Fonds Deutschland, grants from Hilde Ulrich Stiftung. WZ reports personal fees from F. Hoffmann-La Roche Ltd and Prothena Ltd. RP reports grants and personal fees from Fonds de la Recherche en Sante, grants from Canadian Institute of Health Research, grants from The Parkinson Society of Canada, grants from Weston-Garfield Foundation, grants from Michael J. Fox Foundation, grants from Webster Foundation, grants from National Institute of Health, grants and personal fees from Roche, personal fees from Takeda, personal fees from Teva Neurosciences, personal fees from Biogen, personal fees from Boehringer Ingelheim, personal fees from Theranexus, personal fees from GE HealthCare, personal fees from Jazz Pharmaceuticals, personal fees from AbbVie, personal fees from Janssen, personal fees from Otsuko, personal fees from Phytopharmica, personal fees from Inception Sciences, other from Parkinson Canada, personal fees from Paladin. ML reports personal fees from F. Hoffmann-La Roche Ltd and has a patent US20190200915A1 pending to Hoffmann-La Roche Inc., a patent EP3701542A2 pending to F. Hoffmann-La Roche AG, a patent WO2019215230A1 pending to F. Hoffmann-La Roche AG, and a patent WO2021055443A1 pending to F. Hoffmann-La Roche AG.Clinical TrialNCT03100149Funding StatementThe authors declare that the study is funded by F. Hoffmann-La Roche Ltd and Prothena Inc. F. Hoffmann-La Roche Ltd and Prothena Inc were involved in the study design, collection, analysis, interpretation of data, the writing of this article and the decision to submit it for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants were identified for potential recruitment using site-specific recruitment plans prior to consenting to take part in this study. Recruitment materials for participants had received Institutional Review Board or Ethics Committee approval prior to use. The following Institutional Review Boards ruled on ethics of the PASADENA study: Ethikkommission der Medizinischen Universität Innnsbruck, Innsbruck, Austria; Comité de Protection des Personnes (CPP) Ouest IV, Nantes, France; Ethikkommission der Universität Leipzig and Geschäftsstelle der Ethikkommission an der medizinischen Fakultät der Universität Leipzig, Leipzig, Germany; Ethikkommission der Fakultät für Medizin der Technischen Universität München, München, Germany; Ethikkommission der Universität Ulm (Oberer Eselsberg), Ulm, Germany; Landesamt für Gesundheit und Soziales Berlin and Geschäftsstelle der Ethik-Kommission des Landes Berlin, Berlin, Germany; Ethikkommission des FB Medizin der Philipps-Universität Marburg, Marburg, Germany; Ethikkommission an der Medizinischen Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen, Tübingen, Germany; Ethikkommission an der Med. Fakultät der HHU Düsseldorf, Düsseldorf, Germany; Ethikkommission der LäK Hessen, Frankfurt, Germany; CEIm Hospital Universitari Vall d'Hebron, Barcelona, Spain; Copernicus Group Independent Review Board, Puyallup, Washington, USA; Western Institutional Review Board, Puyallup, Washington, USA; The University of Kansas Medical Center Human Research Protection Program, Kansas City, Kansas, USA; Oregon Health & Science University Independent Review Board, Portland, Oregon, USA; Northwestern University Institutional Review Board, Chicago, Illinois, USA; Spectrum Health Human Research Protection Program, Grand Rapids, Michigan, USA; The University of Vermont Committees on Human Subjects, Burlington, Vermont, USA; Beth Israel Deaconess Medical Center Committee on Clinical Investigations, New Procedures and New Forms of Therapy, Boston, Massachusetts, USA; Vanderbilt Human Research Protection Program Health, Boston, Massachusetts, USA; Vanderbilt Human Research Protection Program Health, Nashville, Tennessee, USA; University of Maryland, Baltimore Institutional Review Board, Baltimore, Maryland, USA; University of Southern California Institutional Review Board, Los Angeles, California, USA; Columbia University Medical Center Institutional Review Board, New York, New York, USA; University of Southern California San Francisco Institutional Review Board, San Francisco, California, USA; University of Pennsylvania Institutional Review Board, Philadelphia, Philadelphia, USA; HCA - HealthOne Institutional Review Board, Denver, Colorado, USA. All Institutional Review Boards gave ethical approval of the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQualified researchers may request access to individual patient-level data through the clinical trial data request platform (https://vivli.org/). Further details on Roche's criteria for eligible trials are available at https://vivli.org/members/ourmembers/. For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical trial documents, see https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm. https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm. ER -